{"prompt": "['2017N331008_06', 'CONFIDENTIAL', '208090', '7.1.1.2.', 'Managing Participants Meeting Precautionary', 'Virologic Withdrawal (PVW) or Confirmed', 'Virologic Withdrawal (CVW) Criteria', '50', '7.1.2.', 'Liver Chemistry Stopping Criteria', '54', '7.1.3.', 'Temporary Discontinuation', '54', '7.1.4.', 'Restart', '54', '7.2.', 'Withdrawal from the Study', '54', '7.3.', 'Lost to Follow Up', '56', '8.', 'STUDY ASSESSMENTS AND PROCEDURES', '57', '8.1.', 'Efficacy Assessments', '59', '8.1.1.', 'Primary Efficacy Endpoint', '59', '8.1.2.', 'Secondary Efficacy Endpoints', '60', '8.2.', 'Safety Assessments', '60', '8.2.1.', 'Physical Examinations', '60', '8.2.2.', 'Vital Signs', '60', '8.2.3.', 'Electrocardiograms', '60', '8.2.4.', 'Clinical Safety Laboratory Assessments', '60', '8.2.5.', 'Suicidal Risk Monitoring', '61', '8.2.6.', 'Pregnancy', '62', '8.3.', 'Adverse Events (AE) and Serious Adverse Events (SAEs)', '63', '8.3.1.', 'Time Period and Frequency for Collecting AE and SAE', 'Information', '63', '8.3.2.', 'Method of Detecting AEs and SAEs', '64', '8.3.3.', 'Follow-up of AEs and SAEs', '64', '8.3.4.', 'Regulatory Reporting Requirements for SAEs', '64', '8.3.5.', 'Cardiovascular and Death Events', '64', '8.3.6.', 'Disease-Related Events and/or Disease-Related', 'Outcomes Not Qualifying as SAEs', '65', '8.4.', 'Treatment of Overdose', '65', '8.5.', 'Pharmacokinetics', '66', '8.6.', 'Pharmacodynamics', '66', '8.7.', 'Genetics', '66', '8.8.', 'Biomarkers', '66', '8.9.', 'Health Economics and Outcomes Research', '67', '8.10.', 'HIV-1 Polymerase Viral Genotyping and Phenotyping', '68', '8.10.1. HIV-1 Exploratory Analysis', '68', '9.', 'STATISTICAL CONSIDERATIONS', '69', '9.1.', 'Statistical Hypotheses', '69', '9.2.', 'Sample Size Determination', '69', '9.2.1.', 'Sample Size Assumptions', '69', '9.2.1.1.', 'Response and virologic failure rate', 'assumptions', '70', '9.2.2.', 'Sample Size Sensitivity', '73', '9.2.3.', 'Sample Size Re-estimation or Adjustment', '73', '9.3.', 'Populations for Analyses', '73', '9.4.', 'Statistical Analyses', '74', '9.4.1.', 'Efficacy Analyses', '74', '9.4.2.', 'Safety Analyses', '76', '9.4.3.', 'Other Analyses', '77', '9.5.', 'Interim Analyses', '77', '8']['2017N331008_06', 'CONFIDENTIAL', '208090', '9.5.1.', 'Independent Data Monitoring Committee (IDMC)', '77', '9.5.2.', 'Analysis Datasets', '78', '9.5.3.', 'Treatment Comparisons', '78', '9.5.3.1.', 'Primary Comparison of Interest', '78', '9.5.3.2.', 'Other Comparisons of Interest', '79', '10. REFERENCES', '80', '11. SUPPORTING DOCUMENTATION AND OPERATIONAL', 'CONSIDERATIONS', '86', '11.1. Appendix 1: Abbreviations and Trademarks', '86', '11.2.', 'Appendix 2: A Sub-study of Virologic Response to Subsequent ART', 'after Discontinuation from 208090 for Meeting CVW or PVW Criteria', '90', '11.2.1.', 'Rationale for CVW and PVW Sub-study', '90', '11.2.2.', 'Sub-study Objectives and Endpoints', '90', '11.2.3.', 'Sub-study Design', '90', '11.2.4.', 'Sub-study data Collection', '92', '11.2.5.', 'Statistical Considerations and Data Analysis', '92', '11.3.', 'Appendix 3: Toxicity Management', '93', '11.3.1.', 'Specific Toxicities/Adverse Event Management', '94', '11.3.1.1. Liver Chemistry Stopping and Follow-up', 'Criteria', '94', '11.3.1.2.', 'Restarting Study Intervention', '95', '11.3.1.3.', 'Decline in Renal Function', '95', '11.3.1.4.', 'Proteinuria', '95', '11.3.1.5.', 'Allergic reaction', '95', '11.3.1.6.', 'Rash', '96', '11.3.1.7.', 'Hypertriglyceridemia/Hypercholesterolemia', '97', '11.4.', 'Appendix 4: Contraceptive Guidance and Collection of Pregnancy', 'Information', '98', '11.4.1. Definitions', '98', '11.4.2.', 'Contraception Guidance', '98', '11.4.3.', 'Collection of Pregnancy Information', '100', '11.5.', 'Appendix 5: Child-Pugh Classification', '101', '11.6.', 'Appendix 6: Prohibited Medications', '102', '11.7.', 'Appendix 7: Clinical Laboratory Tests', '104', '11.8.', 'Appendix 8: Adverse Events: Definitions and Procedures for', 'Recording, Evaluating, Follow-up, and Reporting', '106', '11.8.1.', 'Definition of AE', '106', '11.8.2.', 'Definition of SAE', '107', '11.8.3.', 'Definition of Cardiovascular Events', '108', '11.8.4.', 'Recording AE and SAE', '109', '11.8.5.', 'Reporting of SAE and other events to ViiV/GSK/PPD', '111', '11.9. Appendix 9: Liver Safety: Required Actions and Follow-up', 'Assessments and Study Intervention Restart Guidelines', '112', '11.9.1. Liver Chemistry Stopping Criteria: Required Actions and', 'Follow up Assessments', '112', '11.9.2.', 'Study Intervention Restart after Stopping for Liver Criteria', '115', '11.10. Appendix 10: Regulatory, Ethical and Study Oversight', 'Considerations', '119', '11.10.1. Regulatory and Ethical Considerations', '119', '11.10.2. Financial Disclosure', '119', '9']\n\n###\n\n", "completion": "END"}